Following the in silico approach, which demonstrated promising characteristics of the designed structures, the subsequent phase involves experimental verification of the most critical properties. To assess these parameters, we utilized the biomimetic chromatography platform developed by Valko at GlaxoSmithKline, which allows for measuring of acid-base properties, lipophilicity, and binding to phospolipids and plasma proteins in a cost-effective and time-saving manner . In Table , the obtained chrom logD7.4, phospholipophilicity index (PFI), and %HSA have been collected. This study utilized chromatographic columns with surface modifications containing HSA, the predominant plasma protein, to estimate drug-HSA binding. Such protein-binding interactions influence key pharmacokinetic parameters, including drug distribution, elimination half-life, and clearance. In the case of our group, their basic nature will make HSA the main plasma protein responsible for their binding. Therefore, results with %HSA for THA remain consistent with the literature %PPB, 56% vs. 55% . In the case of the newly synthesized derivatives, a significant increase in binding to HSA is observed. This can partly be explained by the lipophilicity pattern, with high correlations between chromatographic logD7.4 and logkHSA (r = 0.84). Nevertheless, maintaining an acceptable level of HSA binding remains critical in drug discovery .